|Articles|January 13, 2023

An Exciting Time in CDI: Approvals, Approaches and Anticipation

The therapies for Clostridioides difficile infection (CDI) saw many developments in recent months and there are more exciting things to come.

CDI saw quite a number of developments in 2022, especially with the approval of first-ever fecal microbiota, RBX2660, for C difficile recurrence at the end of the year.

There has been research looking at different approaches and the economics of CDI. In addition, there is another prospective approval pending for CDI this year.

Check out our slideshow to find more information on the approval, a differing approach, the economics of CDI, and what’s ahead.

To read the articles for the individual slides, click on the individual slides below:

Slide 1

Slide 2

Slide 3

Slide 4

Stay ahead of emerging infectious disease threats with expert insights and breaking research. Subscribe now to get updates delivered straight to your inbox.

Related to this article

September 23rd, 2026

Asymptomatic C difficile Colonization in Infants Doesn’t Mean Benign

A new study in infants challenges the long-standing belief about the pathogen’s effects in the youngest pediatric population. Senior author Joseph Zackular, PhD, provides insights around his work including how it reshapes gut development and offers potential intervention strategies to shield neonates.

$FDA Approves Pritelivir for Refractory HSV in Immunocompromised Adults$

October 10th, 2026

FDA Approves Pritelivir for Refractory HSV in Immunocompromised Adults

Pritelivir (Hovilpri) healed all lesions by day 28 in 63% of immunocompromised adults with refractory HSV versus 34% with investigator's choice in the phase 3 PRIOH-1 trial.

October 10th, 2026

Active Outbreaks Tied to Sprouts, Cheese and Turtles

CDC is continuing its investigation into 4 multistate Salmonella and E coli outbreaks, led by a 76-case alfalfa sprout cluster across 16 states and a recalled raw milk cheese.

October 9th, 2026

Measles Update: October 9, 2026

The latest CDC numbers show a 5.0% increase of measles cases from week-to-week. The US total reached 4080 confirmed cases, 78% above all of 2025.

October 9th, 2026

New UTI Guidelines: Addressing the Shift to Localized, Systemic Infection Classification

UTI guidelines are moving away from complicated or uncomplicated infections to localized or systemic classification terminologies. Guidelines author Zachary Nelson, PharmD, MPH, BCIDP, provides further insights on the changes including applying antibiograms, potential costs, and whether clinicians will embrace these new classifications.

October 8th, 2026

Implementation Science Could Close the Know-Do Gap, Potential Future of Research

Demonstrating a diagnostic test works is no longer enough. Clinicians and laboratories also need evidence on how to adopt it in everyday practice. Andrea Prinzi, PhD, MPH, SM(ASCP), explains how implementation science can help infectious disease and clinical microbiology teams turn evidence into routine care.

October 8th, 2026

Ebola Deaths Top 4,100 as Kenya Confirms First Imported Bundibugyo Case

Kenya reported its first imported Bundibugyo Ebola death as the Democratic Republic of Congo (DRC) outbreak surpassed 8,600 confirmed cases and 4,148 deaths, with 896 patients hospitalized in isolation. Here is a report on the latest numbers as well as vaccine and therapeutic study updates.

October 7th, 2026

FAQ: Measles

With US measles cases nearing 3,900 this year and Pennsylvania reporting its fifth measles-related death, here is a review of how the virus spreads, how it is prevented and managed, and what severe disease looks like.